BeiGene, Ltd. (BGNE)
| Previous close | 144.12 |
| Open | 148.40 |
| Bid | 148.21 x 100 |
| Ask | 149.65 x 200 |
| Day's range | 146.16 - 149.31 |
| 52-week range | 126.97 - 266.67 |
| Volume | |
| Avg. volume | 243,108 |
| Market cap | 16.336B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.45 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 272.37 |
Insider Monkey20 Countries with the Highest Rates of Stomach Cancer in the World
In this article, we will be taking a look at the 20 countries with the highest rates of stomach cancer in the world. If you do not want to learn about the global cancer trends, head straight to the 5 Countries with the Highest Rates of Stomach Cancer in the World. Overview of the Global […]
Business WireGlobal Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 24, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024.
Simply Wall St.With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners
Key Insights Significantly high institutional ownership implies BeiGene's stock price is sensitive to their trading...
